KRAS and BRAF Mutations in Patients with Hepatocellular Carcinoma in Senegal

Hepatocellular carcinoma (HCC) is a public health problem in developing countries where chronic HBV endemic. The objective of our study was to determine the prevalence KRAS and BRAF mutations patients with HCC. Mutations codons 12 13 V600E mutation gene were searched by HRM on Light Cycler 480 confirmed direct sequencing. A total 34 HCC underwent molecular testing for codon gene. Melting curve analysis showed 23.5% (n=8/34) 41.2% (n=14/34) mean age carriers lower compared carriers. Chronic carriage appeared play role development these mutations, increasing risk 2 (CI(95)=0.55-7.24; p=0.395) 1.78 (CI(95)=0.23-13.5; p=1) KRAS. do not appear tumor metastasis. However, results need be further studies larger sample size. Alterations RAS/RAF/MAP Kinase pathway more prominent HBV-induced This may hinder management receptor tyrosine kinase inhibitors, basis treatment advanced